Efficacy and Safety of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P08034 AM4)

Inclusion Criteria:

- CHC GT1 infection for at least 6 months with with HCV-RNA ≥10,000 IU/mL.

- Treatment naive, non-cirrhotic participants will be eligible for inclusion in Study
Part A

- Non-cirrhotic subjects who failed previous (peg)interferon/ribavirin treatment for
CHC and cirrhotics, whether treatment naive or treatment failure, will be eligible
for inclusion in Study Part B

- To participate in Study Part C, participants must have completed the required
post-treatment follow-up in Study Part A or Part B

- Weight ≥ 10 kg to ≤ 125 kg

- Body surface area (BSA) ≥0.46 m^2 and ≤2.5 m^2

- Previous liver biopsy with histology consistent with chronic hepatitis C and no other
etiology within 2 years of the screening visit

- Participants with bridging fibrosis or cirrhosis must have an ultrasound within 6
months of the screening visit or between the screening visit and Day 1 with no
findings suspicious for hepatocellular carcinoma

- Participant must be able to adhere to dose and visit schedules

Exclusion Criteria:

- Known co-infection with the the human immunodeficiency virus (HIV) or hepatitis B
virus (HBsAg positive)

- For Study Part A, participant received any prior hepatitis C treatment, including
herbal remedies, with known hepatotoxicity

- For Study Part B, participant received treatment with ribavirin within 90 days or any
interferon alpha within 30 days prior to screening

- For Study Part B, participant received previous treatment with a hepatitis C virus
protease inhibitor (excepting participants in study P07614, Pharmacokinetics of
Boceprevir in Pediatric Subjects With Chronic Hepatitis C Genotype 1)

- For Study Part B, participant required discontinuation of previous
(peg)interferon/ribavirin therapy for an adverse event considered by the investigator
to be related to (peg)interferon and/or ribavirin

- For Study Part B, participant is currently taking any antiviral/immunomodulatory
treatment for hepatitis C

- Participant has taken any investigational drugs, except boceprevir

- Participant has received any of the following medication(s) within 2 weeks prior to
the Day 1 visit: midazolam, pimozide, amiodarone, flecainide, propafenone, quinidine,
and ergot derivatives (dihydroergotamine, ergonovine, ergotamine, methylergonovine)

- Participation in any other clinical trial within 30 days of enrollment or intent to
participate in another clinical trial during participation in the current study

- Evidence of decompensated liver disease

- Child Pugh score >6 (class B and C)

- History of diabetes or hypertension or was born prior to 32 weeks of gestation and
has clinically significant ocular examination findings

- Pre-existing clinically significant psychiatric condition(s)

- Clinical diagnosis of substance abuse

- Any pre-existing medical condition that could interfere with participation in and
completion of the study

- Evidence of active or suspected malignancy

- Females who are pregnant, nursing, or intend to become pregnant during the study
period

- Allergy or sensitivity to the investigational products or excipients